Charles Schwab Investment Management Inc. Decreases Stock Holdings in Quanterix Co. (NASDAQ:QTRX)

Charles Schwab Investment Management Inc. reduced its holdings in Quanterix Co. (NASDAQ:QTRX) by 18.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 266,615 shares of the company’s stock after selling 58,989 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Quanterix were worth $2,834,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Portolan Capital Management LLC lifted its holdings in shares of Quanterix by 31.4% in the 3rd quarter. Portolan Capital Management LLC now owns 2,520,686 shares of the company’s stock valued at $32,668,000 after acquiring an additional 602,656 shares during the last quarter. Valmark Advisers Inc. raised its position in Quanterix by 88.3% during the fourth quarter. Valmark Advisers Inc. now owns 210,878 shares of the company’s stock valued at $2,242,000 after purchasing an additional 98,883 shares during the period. Pier Capital LLC lifted its stake in shares of Quanterix by 23.5% in the 3rd quarter. Pier Capital LLC now owns 511,798 shares of the company’s stock valued at $6,633,000 after purchasing an additional 97,256 shares during the last quarter. Graypoint LLC purchased a new position in shares of Quanterix in the 4th quarter worth approximately $691,000. Finally, Algert Global LLC increased its position in shares of Quanterix by 75.9% during the 3rd quarter. Algert Global LLC now owns 137,833 shares of the company’s stock valued at $1,786,000 after purchasing an additional 59,496 shares during the last quarter. 86.48% of the stock is currently owned by institutional investors.

Quanterix Stock Performance

Shares of QTRX stock opened at $6.77 on Friday. The stock has a 50 day moving average price of $8.04 and a 200 day moving average price of $10.69. Quanterix Co. has a 52-week low of $6.30 and a 52-week high of $23.94. The firm has a market capitalization of $262.51 million, a P/E ratio of -6.39 and a beta of 1.33.

Quanterix (NASDAQ:QTRX) last released its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The business had revenue of $35.16 million for the quarter, compared to the consensus estimate of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. As a group, sell-side analysts forecast that Quanterix Co. will post -0.98 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on QTRX shares. Scotiabank restated an “outperform” rating on shares of Quanterix in a research report on Tuesday. Canaccord Genuity Group reduced their target price on shares of Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday, March 18th.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.